

1 March 2017 EMA/668803/2016 Press office

## Recommendations on eligibility to PRIME scheme

Adopted at the CHMP meeting of 20-23 February 2017

During its February 2017 meeting, the CHMP reviewed 5 recommendations for eligibility to PRIME: 2 were granted and 3 were denied. The individual outcomes adopted this month are listed below.



© European Medicines Agency, 2017. Reproduction is authorised provided the source is acknowledged.

## **Eligibility granted**

Name*	Substance type	Therapeutic area	Therapeutic indication	Type of data supporting request	Type of applicant
Adeno-associated viral vector containing factor IX gene variant (PF- 06838435/SPK- 9001)	Advanced therapy	Haematology - Hemostaseology	Treatment of haemophilia B	Nonclinical + Clinical exploratory	Other
Givosiran	Chemical	Endocrinology- Gynaecology- Fertility-Metabolism	Prevention of acute attacks of hepatic porphyria	Nonclinical + Clinical exploratory	Other

\* Name of the active substance, INN, common name, chemical name or company code.


SME applicants are micro-, small-and medium-sized-enterprises registered with the Agency's SME office. Other types of applicants are those not qualifying or not registered as SME or not fulfilling the definition of academic sponsors.

## **Eligibility denied**

Substance type	Therapeutic area	Therapeutic indication	Type of data supporting request	Type of applicant
Radiopharmaceutical	Oncology	Conditioning treatment for haematopoietic stem cell transplantationin patients with Acute myeloid leukaemia	Nonclinical + Clinical exploratory	SME
Immunological	Infectious Diseases	Prevention of postoperative invasive disease caused by Staphylococcus aureus	Nonclinical + Clinical exploratory	Other
Chemical	Immunology- Rheumatology- Transplantation	Treatment of antiphospholipid syndrome	Nonclinical + Clinical exploratory	Academic

SME applicants are micro-, small-and medium-sized-enterprises registered with the Agency's SME office. Other type of applicants are those not qualifying or not registered as SME or not fulfilling the definition of academic sponsors.

## Cumulative overview of recommendations on PRIME eligibility requests adopted by 23 February 2017



\* This indicates eligibility requests received but not started by EMA as they were deemed outside the scope of the scheme or with a format and content inadequate to support their review. These are not included in the breakdown by type of applicant or by therapeutic area.